Polo‐like kinase 3 is associated with improved overall survival in cholangiocarcinoma. (10th April 2015)
- Record Type:
- Journal Article
- Title:
- Polo‐like kinase 3 is associated with improved overall survival in cholangiocarcinoma. (10th April 2015)
- Main Title:
- Polo‐like kinase 3 is associated with improved overall survival in cholangiocarcinoma
- Authors:
- Juntermanns, Benjamin
Sydor, Svenja
Kaiser, Gernot M.
Jaradat, Derar
Mertens, Joachim C.
Sotiropoulos, Georgios C.
Swoboda, Sandra
Neuhaus, Jan P.
Meng, Wei
Mathé, Zoltan
Baba, Hideo A.
Canbay, Ali
Paul, Andreas
Fingas, Christian D. - Abstract:
- <abstract abstract-type="main" id="liv12839-abs-0001"> <title>Abstract</title> <sec id="liv12839-sec-0001" sec-type="section"> <title>Background &amp; Aims</title> <p>Cholangiocarcinomas (CCA) paradoxically express the death ligand TRAIL and thus, are dependent on effective survival signals to circumvent apoptosis. Hedgehog signalling exerts major survival signals in CCA by regulating serine/threonine kinase polo‐like kinase (PLK)2. We here aimed to examine the role of PLK1/2/3 expression for CCA tumour biology.</p> </sec> <sec id="liv12839-sec-0002" sec-type="section"> <title>Methods</title> <p>We employed CCA samples from 73 patients and human HUCCT–1/Mz–CHA1/KMCH‐1 CCA cells. Immunohistochemistry for PLK1/2/3 was performed using tissue microarrays from representative tumour areas.</p> </sec> <sec id="liv12839-sec-0003" sec-type="section"> <title>Results</title> <p>PLK1/2/3‐immunoreactive cancer cells were present in most of the CCA samples. However, only PLK1 and especially PLK3 were expressed in higher amounts within CCA cells as compared to normal liver. Given that fibroblast growth factor (FGF) can induce PLK3 expression and also is present in CCA, we examined the effect of FGF on PLK3 <italic>in vitro</italic>. Indeed, rhFGF rapidly increased <italic>PLK3 </italic>mRNA expression all three CCA cell lines giving an explanation for the abundant PLK3 presence in the tissue samples. Clinicopathologically, PLK3 expression was associated with decreased tumour cell migration<abstract abstract-type="main" id="liv12839-abs-0001"> <title>Abstract</title> <sec id="liv12839-sec-0001" sec-type="section"> <title>Background &amp; Aims</title> <p>Cholangiocarcinomas (CCA) paradoxically express the death ligand TRAIL and thus, are dependent on effective survival signals to circumvent apoptosis. Hedgehog signalling exerts major survival signals in CCA by regulating serine/threonine kinase polo‐like kinase (PLK)2. We here aimed to examine the role of PLK1/2/3 expression for CCA tumour biology.</p> </sec> <sec id="liv12839-sec-0002" sec-type="section"> <title>Methods</title> <p>We employed CCA samples from 73 patients and human HUCCT–1/Mz–CHA1/KMCH‐1 CCA cells. Immunohistochemistry for PLK1/2/3 was performed using tissue microarrays from representative tumour areas.</p> </sec> <sec id="liv12839-sec-0003" sec-type="section"> <title>Results</title> <p>PLK1/2/3‐immunoreactive cancer cells were present in most of the CCA samples. However, only PLK1 and especially PLK3 were expressed in higher amounts within CCA cells as compared to normal liver. Given that fibroblast growth factor (FGF) can induce PLK3 expression and also is present in CCA, we examined the effect of FGF on PLK3 <italic>in vitro</italic>. Indeed, rhFGF rapidly increased <italic>PLK3 </italic>mRNA expression all three CCA cell lines giving an explanation for the abundant PLK3 presence in the tissue samples. Clinicopathologically, PLK3 expression was associated with decreased tumour cell migration and lymph/blood vessel infiltration whereas higher levels of PLK1 were correlated with larger tumour sizes. Moreover, strong PLK3 expression was associated with prolonged overall survival.</p> </sec> <sec id="liv12839-sec-0004" sec-type="section"> <title>Conclusions</title> <p>The results suggest that PLK3 predominantly is expressed in CCA cells and that high PLK3 expression correlates with prolonged overall survival. These observations might have implications for prognosis prediction of human CCA as well as the potential therapeutic use of polo‐like kinase inhibitors (i.e., PLK1/2 specifity).</p> </sec> </abstract> … (more)
- Is Part Of:
- Liver international. Volume 35:Number 11(2015:Nov.)
- Journal:
- Liver international
- Issue:
- Volume 35:Number 11(2015:Nov.)
- Issue Display:
- Volume 35, Issue 11 (2015)
- Year:
- 2015
- Volume:
- 35
- Issue:
- 11
- Issue Sort Value:
- 2015-0035-0011-0000
- Page Start:
- 2448
- Page End:
- 2457
- Publication Date:
- 2015-04-10
- Subjects:
- Liver -- Periodicals
Liver -- Diseases -- Periodicals
616.362 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1478-3231 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/liv.12839 ↗
- Languages:
- English
- ISSNs:
- 1478-3223
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5280.514000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 3218.xml